EGFR and non-small cell squamous lung carcinoma: The OPAL study [44], a phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small-cell lung cancer, consistently showed excellent efficacy, with the ORR, CRR, and DCR being 90.9% (95% confidence interval [CI], 84.0–97.8), 3.0% (0.0–7.2), and 97.0% (92.8–100.0), respectively.